Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies

Atrium Therapeutics, Inc. (Nasdaq: RNA) launched today as a newly independent, publicly traded company dedicated to delivering RNA therapeutics directly to the heart to transform care for people ...
TMCnet

WuXi XDC Enters Strategic Collaboration with Earendil Labs on WuXiTecan-2 Payload-Linker Technology Platform

Under the agreement, WuXi XDC will grant Earendil Labs an exclusive global license to its proprietary WuXiTecan-2 ...
The Manila Times

Earendil Labs Enters Strategic Collaboration with WuXi XDC on WuXiTecan-2 Payload-Linker Technology Platform

Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, today announced a strategic collaboration with WuXi XDC Cayman Inc. ('WuXi XDC', stock ...
Stocktwits on MSN

SPRB stock drops after company pushes back application submission timeline for experimental Sanfilippo syndrome therapy

The company had previously said that it expects to submit an application for approval of the therapy in the first quarter of 2026. ・In the December meeting with the FDA, the company discussed its ...
InvestorsHub on MSN

Spruce Biosciences reports positive FDA meetings as it prepares TA-ERT filing for rare pediatric disorder

Spruce Biosciences, Inc. (NASDAQ:SPRB) said it has completed two Type B meetings with the U.S. Food and Drug Administration (FDA), clearing key regulatory discussions ahead of its planned biologics ...
Le Lézard

Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today ...
BioProcess International

Engineering Outer-Membrane Vesicles: Leverage Rational Design To Shape the Future of Vaccine Development

Platform-enabled vaccine design unlocks safer, more effective solutions with outer-membrane vesicles (OMVs) emerging as ...
Deccan Chronicle

Manufacturing, Access Key to Scaling Next-Gen Biologics, Say Experts

Simpson Emmanuel detailed progress in indigenous CAR-T therapy, describing it as a personalised treatment where a patient’s ...

Devonian Advances Thykamine™ Patent Strategy with Proprietary Fingerprint and Robust Manufacturing Controls

Devonian Health Group Inc. ("Devonian" or the Company) (TSXV: GSD) (OTCQB: DVHGF) today announced that a proprietary ...

OS Therapies Initiates FDA BLA Filing for OST-HER2 to Prevent or Delay Recurrent Pulmonary Metastatic Osteosarcoma

Regenerative Medicine Advanced Therapy (RMAT) designation requests update submitted to FDA with recent biomarker data ...

Ernest Pharmaceuticals announces FDA INTERACT meeting for EBT-302, a bacterial therapy targeting advanced liver cancer

This productive discussion with FDA reviewers gives Ernest leadership renewed confidence our development plan is on the ...
BioSpace

NurExone Biologic Advances Manufacturing and Regulatory Roadmap with Independent Batch Consistency Results for Exosome Production

Toronto, Ontario and Haifa, Israel--(Newsfile Corp. - February 10, 2026) - NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company ...